Literature DB >> 29373716

Epidemiological trends of cryptococcosis in Italy: Molecular typing and susceptibility pattern of Cryptococcus neoformans isolates collected during a 20-year period.

Massimo Cogliati1, Anna Prigitano1, Maria Carmela Esposto1, Luisa Romanò1, Anna Grancini2, Alberto Zani1, Anna Maria Tortorano1.   

Abstract

In the present study clinical data and isolates from cases of cryptococcosis recorded during clinical surveys carried out in Italy from 1997 to 2016, were investigated. Molecular typing and antifungal susceptibility testing were performed in order to delineate the epidemiological trend of cryptococcosis in Italy and to define wild-type population for four different antifungal compounds. During the studied period, a total of 302 cases collected from 32 centers of 11 Italian regions were recorded. Analysis of clinical data showed a significant increase of frequency (from 7% to 38%) of cryptococcosis in human immunodeficiency virus (HIV)-negative patients primarily with hematologic malignancies and solid organ transplantations. The prevalence of the molecular types has significantly changed during the study period, showing an increase of VNIII isolates from 11% to 41% in HIV-negative patients, and a decrease of VNIV isolates from 36% to 16%. Antifungal susceptibility testing allowed us to calculate the epidemiological cut-off for flucytosine (1 mg/l), fluconazole (8 mg/l), itraconazole (0.5 mg/l), and voriconazole (0.25 mg/l). Most of the isolates were wild-type strains. Comparison of the MIC distributions according to molecular types showed that VNIV isolates had lower MICs for fluconazole and itraconazole than the VNI and VIII isolates. The current study emphasizes that the epidemiology of cryptococcosis in Italy has significantly changed over the last decades.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29373716     DOI: 10.1093/mmy/myx152

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  3 in total

1.  The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.

Authors:  Trieu Phan Hai; Anh Duong Van; Nguyen Thi Thuy Ngan; Le Thanh Hoang Nhat; Nguyen Phu Huong Lan; Nguyen V Vinh Chau; Guy E Thwaites; Damian Krysan; Jeremy N Day
Journal:  Mycoses       Date:  2019-06-23       Impact factor: 4.377

2.  Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model.

Authors:  Supavit Chesdachai; Radha Rajasingham; Melanie R Nicol; David B Meya; Felix Bongomin; Mahsa Abassi; Caleb Skipper; Richard Kwizera; Joshua Rhein; David R Boulware
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

3.  CryptoType - Public Datasets for MALDI-TOF-MS Based Differentiation of Cryptococcus neoformans/gattii Complexes.

Authors:  Mareike Bernhard; Navaporn Worasilchai; Mourine Kangogo; Christine Bii; Wioleta J Trzaska; Michael Weig; Uwe Groß; Ariya Chindamporn; Oliver Bader
Journal:  Front Cell Infect Microbiol       Date:  2021-04-19       Impact factor: 5.293

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.